TY - JOUR
T1 - DCRM 2.0
T2 - Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
AU - Handelsman, Yehuda
AU - Anderson, John E.
AU - Bakris, George L.
AU - Ballantyne, Christie M.
AU - Bhatt, Deepak L.
AU - Bloomgarden, Zachary T.
AU - Bozkurt, Biykem
AU - Budoff, Matthew J.
AU - Butler, Javed
AU - Cherney, David Z.I.
AU - DeFronzo, Ralph A.
AU - Del Prato, Stefano
AU - Eckel, Robert H.
AU - Filippatos, Gerasimos
AU - Fonarow, Gregg C.
AU - Fonseca, Vivian A.
AU - Garvey, W. Timothy
AU - Giorgino, Francesco
AU - Grant, Peter J.
AU - Green, Jennifer B.
AU - Greene, Stephen J.
AU - Groop, Per Henrik
AU - Grunberger, George
AU - Jastreboff, Ania M.
AU - Jellinger, Paul S.
AU - Khunti, Kamlesh
AU - Klein, Samuel
AU - Kosiborod, Mikhail N.
AU - Kushner, Pamela
AU - Leiter, Lawrence A.
AU - Lepor, Norman E.
AU - Mantzoros, Christos S.
AU - Mathieu, Chantal
AU - Mende, Christian W.
AU - Michos, Erin D.
AU - Morales, Javier
AU - Plutzky, Jorge
AU - Pratley, Richard E.
AU - Ray, Kausik K.
AU - Rossing, Peter
AU - Sattar, Naveed
AU - Schwarz, Peter E.H.
AU - Standl, Eberhard
AU - Steg, P. Gabriel
AU - Tokgözoğlu, Lale
AU - Tuomilehto, Jaakko
AU - Umpierrez, Guillermo E.
AU - Valensi, Paul
AU - Weir, Matthew R.
AU - Wilding, John
AU - Wright, Eugene E.
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024
Y1 - 2024
N2 - The spectrum of cardiorenal and metabolic diseases comprises many disorders, including obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), dyslipidemias, hypertension, and associated comorbidities such as pulmonary diseases and metabolism dysfunction–associated steatotic liver disease and metabolism dysfunction–associated steatohepatitis (MASLD and MASH, respectively, formerly known as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [NAFLD and NASH]). Because cardiorenal and metabolic diseases share pathophysiologic pathways, two or more are often present in the same individual. Findings from recent outcome trials have demonstrated benefits of various treatments across a range of conditions, suggesting a need for practice recommendations that will guide clinicians to better manage complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. To meet this need, we formed an international volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM 2.0 Practice Recommendations, an updated and expanded revision of a previously published multispecialty consensus on the comprehensive management of persons living with DCRM. The recommendations are presented as 22 separate graphics covering the essentials of management to improve general health, control cardiorenal risk factors, and manage cardiorenal and metabolic comorbidities, leading to improved patient outcomes.
AB - The spectrum of cardiorenal and metabolic diseases comprises many disorders, including obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), dyslipidemias, hypertension, and associated comorbidities such as pulmonary diseases and metabolism dysfunction–associated steatotic liver disease and metabolism dysfunction–associated steatohepatitis (MASLD and MASH, respectively, formerly known as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [NAFLD and NASH]). Because cardiorenal and metabolic diseases share pathophysiologic pathways, two or more are often present in the same individual. Findings from recent outcome trials have demonstrated benefits of various treatments across a range of conditions, suggesting a need for practice recommendations that will guide clinicians to better manage complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. To meet this need, we formed an international volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM 2.0 Practice Recommendations, an updated and expanded revision of a previously published multispecialty consensus on the comprehensive management of persons living with DCRM. The recommendations are presented as 22 separate graphics covering the essentials of management to improve general health, control cardiorenal risk factors, and manage cardiorenal and metabolic comorbidities, leading to improved patient outcomes.
U2 - 10.1016/j.metabol.2024.155931
DO - 10.1016/j.metabol.2024.155931
M3 - Review
C2 - 38852020
AN - SCOPUS:85197099462
VL - 159
JO - Metabolism
JF - Metabolism
SN - 0026-0495
M1 - 155931
ER -